SJ

Shengfang Jin

President and CEO

Ensem Therapeutics

Boston, Massachusetts


Contact Information

Email
Unlock
LinkedIn

Company Information

Company
Ensem Therapeutics
Industry
biotechnology
Employees
25.0
Seniority
C suite
Annual Revenue
1300000.0
Total Funding
67000000.0
Latest Funding
Series A

Technologies

Outlook GoDaddy Hosting Mobile Friendly WordPress.org Vimeo Varnish Remote AI

Keywords

precision medicine small molecule drugs cryptic binding pockets structure-based drug design oncology ai deep learning computational methodologies drug discovery kinetic ensemble platform high-value targets difficult-to-drug targets binding pocket prediction ligand design kinetic ensemble technology biophysical technologies pharmacokinetic modeling drug metabolism & pharmacokinetics dmpk clinical trial phases phase i clinical trials bioavailability experimental techniques metastable states de novo drug design synthetic optimization protein dynamics computational chemistry translational research cancer therapies epigenetic therapies clinical-stage drug development biomedical research drug candidates preclinical research scalable technologies targeted oncology drug design strategies novel therapeutic targets molecular dynamics simulations therapeutic innovation multi-target strategy high-throughput screening hybrid modeling intelligent algorithms drug efficacy research & development therapeutic intervention biotechnology innovation protein-ligand interactions hospital & health care

Get Full Contact Details

Subscribe to reveal email addresses and export contacts.

View Plans